CHMP no for AB Science's canine anticancer in humans
This article was originally published in Scrip
Executive Summary
AB Science's share price was down by 19% by mid-afternoon trading on 22 November after the advisory committee to the European Medicines Agency recommended against the approval of its lead product to treat stomach and bowel cancer. The product is already sold as an anticancer for dogs in the US and Europe.